• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    1/10/24 1:06:18 PM ET
    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Industrials
    Get the next $ACRS alert in real time by email

    Shares of WD-40 Company (NASDAQ:WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.

    WD-40 reported quarterly earnings of $1.28 per share which exceeded the analyst consensus estimate of $1.05 per share. The company reported quarterly sales of $140.42 million, clocking in above the Street's estimate of $134.37 million.

    WD-40 shares jumped 17.3% to $277.56 on Wednesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Nauticus Robotics, Inc. (NASDAQ:KITT) climbed 87.8% to $0.5501. Nauticus Robotics secured additional funding and appointed John W. Gibson, Jr as interim CEO.
    • Clearmind Medicine Inc. (NASDAQ:CMND) shares jumped 47.7% to $3.0570. Clearmind Medicine completed a Type A Meeting with the FDA for clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of alcohol use disorder.
    • Sana Biotechnology, Inc. (NASDAQ:SANA) gained 46.8% to $7.57. Sana Biotechnology recently announced FDA clearance of investigational new drug application for SC262.
    • Ucommune International Ltd (NASDAQ:UK) jumped 37.8% to $4.98.
    • Vicarious Surgical Inc. (NASDAQ:RBOT) rose 37% to $0.6851.
    • Nvni Group Limited (NASDAQ:NVNI) climbed 35.2% to $2.6091.
    • EchoStar Corporation (NASDAQ:SATS) gained 31% to $16.50. EchoStar completed merger with DISH Network Corporation.
    • Amarin Corporation plc (NASDAQ:AMRN) climbed 28.8% to $1.25 after the company reported strong preliminary FY23 total revenues.
    • Exicure, Inc. (NASDAQ:XCUR) shares rose 17% to $0.5501. Exicure was granted broad U.S. patent #11866700 for "Liposomal Nucleic Acid Constructs Presenting Antisense Oligonucleotides For Knockdown Of Interleukin 17 Mrna (For Inflammation From Cancer, Obesity, Diabetes, Alzheimer's)."
    • NexImmune, Inc. (NASDAQ:NEXI) gained 16.2% to $13.72.
    • Exscientia plc (NASDAQ:EXAI) rose 14% to $7.07. B of A Securities recently downgraded the stock from Buy to Neutral and lowered its price target from $11 to $9.
    • NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) rose 13.6% to $14.00.
    • SMART Global Holdings Inc. (NASDAQ:SGH) gained 13.4% to $20.97 after the companyy posted better-than-expected earnings for its first quarter and announced approval of $75 million share repurchase authorization.
    • Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) jumped 12.4% to $2.7100. Xeris Biopharma entered into an exclusive worldwide license agreement with Amgen for Xeriject formulation of teprotumumab for thyroid eye disease.
    • GoodRx Holdings, Inc. (NASDAQ:GDRX) jumped 11.6% to $6.38. GoodRx sees preliminary FY23 adjusted revenue of $759 million to $761 million.
    • E2open Parent Holdings, Inc. (NYSE:ETWO) surged 11.2% to $4.27 following strong quarterly sales.
    • PriceSmart, Inc. (NASDAQ:PSMT) rose 10% to $80.25 as the company reported better-than-expected earnings for its first quarter on Tuesday.
    • iCoreConnect Inc. (NASDAQ:ICCT) shares rose 9.3% to $1.4203. iCoreConnect announced strategic acquisition of Verifi Dental.
    • AZZ Inc. (NYSE:AZZ) jumped 9.1% to $62.24 following upbeat quarterly results.
    • Intuitive Surgical, Inc. (NASDAQ:ISRG) gained 6.1% to $350.63. Intuitive Surgical said it sees preliminary revenue of $1.93 billion for the fourth quarter, versus market estimates of $1.87 billion.

    Losers

    • DocGo Inc. (NASDAQ:DCGO) shares fell 32.9% to $3.2150. Fuzzy Panda Research issued a report and disclosed a short position in the stock.
    • HWH International Inc. (NASDAQ:HWH) shares fell 25.3% to $2.10 after dipping 26% on Tuesday.
    • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) fell 25% to $0.9601 after the company's Phase 2B study of ATI-1777 2% QD was not statistically superior on the primary efficacy endpoint.
    • Presto Automation Inc. (NASDAQ:PRST) fell 19.5% to $0.3127.
    • Roma Green Finance Limited (NASDAQ:ROMA) shares fell 18.8% to $2.3557 after dipping over 27% on Tuesday. Roma Green Finance announced pricing of $12.3 million public offering of 2,449,943 of shares at price of $4.00 per share.
    • Sidus Space, Inc. (NASDAQ:SIDU) fell 16.8% to $14.11. Sidus Space regained compliance with Nasdaq minimum bid requirements.
    • Wearable Devices Ltd. (NASDAQ:WLDS) fell 15.7% to $0.3797.
    • Aehr Test Systems (NASDAQ:AEHR) shares fell 15.1% to $18.97 after the company lowered its full-year revenue guidance.
    • Ainos, Inc. (NASDAQ:AIMD) fell 14.9% to $2.22.
    • GrafTech International Ltd. (NYSE:EAF) fell 14.4% to $1.61.
    • Alaunos Therapeutics, Inc. (NASDAQ:TCRT) declined 12.9% to $0.1335.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) fell 12.4% to $18.38 after the company reported preliminary BRIUMVI US net product sales for Q4 and FY23.
    • Wheels Up Experience Inc. (NYSE:UP) fell 12% to $4.2350.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) fell 11.9% to $0.2621 after gaining 22% on Tuesday.
    • Veradigm Inc. (NASDAQ:MDRX) fell 11.1% to $9.56. Veradigm said it sees FY23 revenue of $608 million to $622 million.
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) shares fell 9.1% to $0.1919 after jumping 41% on Tuesday.
    • Saratoga Investment Corp. (NYSE:SAR) fell 9.1% to $23.55 following downbeat quarterly earnings.
    • NovoCure Limited (NASDAQ:NVCR) declined 8.8% to $13.43.
    • Sasol Limited (NYSE:SSL) shares fell 6.8% to $9.08.

     

    Now Read This: How To Earn $500 A Month From JPMorgan Stock Ahead Of Q4 Earnings Report

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $AEHR
    $AIMD
    $AMRN

    CompanyDatePrice TargetRatingAnalyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    3/18/2026$57.00Buy
    Truist
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Sasol Ltd.
    $SSL
    3/5/2026Buy → Neutral
    UBS
    AZZ Inc.
    $AZZ
    3/2/2026$132.00Overweight → Equal Weight
    Wells Fargo
    Aehr Test Systems
    $AEHR
    3/2/2026Mkt Perform → Outperform
    William Blair
    GoodRx Holdings Inc.
    $GDRX
    2/27/2026Overweight → Neutral
    Analyst
    Sasol Ltd.
    $SSL
    2/9/2026Buy → Neutral
    Goldman
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    More analyst ratings

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on NewAmsterdam Pharma with a new price target

    Truist initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $57.00

    3/18/26 3:54:27 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Sasol downgraded by UBS

    UBS downgraded Sasol from Buy to Neutral

    3/5/26 10:20:38 AM ET
    $SSL
    Oil & Gas Production
    Energy

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MicroCloud Hologram Inc. Reports 39.1% Increase in Total Revenue for Fiscal 2025

    SHENZHEN, China, March 27, 2026 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ:HOLO) ("MicroCloud" or the "Company") today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). MicroCloud is dedicated to the research, development, and application of holographic technology, striving to offer leading holographic technology services to customers. The Company delivered strong operating and financial performance in 2025, highlighted by robust revenue growth, continued net loss improvement and a substantial strengthening of liquidity and capital resources.Financial Highlights for Fisca

    3/27/26 1:47:00 PM ET
    $HOLO
    Computer Software: Programming Data Processing
    Technology

    Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

    - Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided additional results from its Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of ITK and Janus kinase 3 (JAK3), presented in an electronic poster at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. "We have continued to achieve importan

    3/27/26 10:10:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

    Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction. The patent application, filed with the Indian Patent Office, forms part of the Company's expanding global intellectual property portfolio and builds upon its exclusive worldwide licens

    3/27/26 7:32:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    SEC Filings

    View All

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/27/26 5:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Inc. filed SEC Form 8-K: Leadership Update

    8-K - EXICURE, INC. (0001698530) (Filer)

    3/27/26 4:40:30 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/27/26 4:19:53 PM ET
    $GDRX
    EDP Services
    Technology

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Patel Dhavalkumar Dhirajlal

    3 - Sana Biotechnology, Inc. (0001770121) (Issuer)

    3/27/26 4:15:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Lurie Ilana

    3 - Wearable Devices Ltd. (0001887673) (Issuer)

    3/23/26 4:01:02 PM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    SEC Form 3 filed by new insider Barel Shmuel

    3 - Wearable Devices Ltd. (0001887673) (Issuer)

    3/23/26 7:08:54 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pendarvis David bought $104,792 worth of shares (424 units at $247.15), increasing direct ownership by 7% to 6,898 units (SEC Form 4)

    4 - WD 40 CO (0000105132) (Issuer)

    2/6/26 6:11:21 PM ET
    $WDFC
    Major Chemicals
    Industrials

    Director Flores William bought $8,900 worth of shares (10,000 units at $0.89), increasing direct ownership by 222% to 14,501 units (SEC Form 4)

    4 - Nauticus Robotics, Inc. (0001849820) (Issuer)

    11/26/25 10:46:20 AM ET
    $KITT
    Industrial Machinery/Components
    Industrials

    Director Brokaw George R bought $68,070 worth of shares (1,000 units at $68.07), increasing direct ownership by 57% to 2,754 units (SEC Form 4)

    4 - EchoStar CORP (0001415404) (Issuer)

    11/20/25 4:40:47 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wearable Devices Strengthens AI Advisory Board with Former Google and Qualcomm Executives to Accelerate ai6 Labs' Vision

    Yokneam Illit, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (NASDAQ:WLDS, WLDSW)) ("Wearable Devices" or the "Company"), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced a significant expansion of its AI expert advisory board. This strategic enhancement strengthens the Company's commitment to advancing neural AI innovation through ai6 Labs. The recently launched ai6 Labs is focused on advancing the Company's revolutionary neural AI technology powered by non-invasive electromyography (EMG) technology and the Mudra platform, supporting a closed-loop ecosystem designed to seamlessly connect hu

    3/16/26 8:45:00 AM ET
    $WLDS
    Computer Communications Equipment
    Telecommunications

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Financials

    Live finance-specific insights

    View All

    Nauticus Robotics, Inc. Announces Timing of 2025 Year-End Investor Earnings Conference Call

    HOUSTON, March 26, 2026 /PRNewswire/ -- Nauticus Robotics, Inc. (NASDAQ:KITT, ", Nauticus", or ", Company", )) today announced the Company's schedule for conducting its financial and operating results call for the year ended December 31, 2025.  The Company plans to host an earnings conference call on April 02, 2026 at 9:00 am Central Time.To participate in the earnings conference call, participants should dial toll free at +1-800-715-9871, conference ID: 9197689, or access the listen-only webcast at the following link: https://events.q4inc.com/attendee/633198435.About Nauticus R

    3/26/26 8:55:00 AM ET
    $KITT
    Industrial Machinery/Components
    Industrials

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sidus Space to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 31 at 5:00 PM ET

    CAPE CANAVERAL, Fla., March 24, 2026 /PRNewswire/ -- Sidus Space, Inc.  (NASDAQ:SIDU) (the "Company" or "Sidus"), an innovative space and technology company, today announced that it will host its fourth quarter 2025 financial results conference call at 5:00 PM Eastern Time on Tuesday, March 31, 2026. Event: Sidus Space Fourth Quarter and Full Year 2025 Financial Results Conference CallDate: Tuesday, March 31, 2026Time: 5:00 PM  Eastern TimeLive Call: 1-866-652-5200 (Toll Free); 1-412-317-6060 (International)Webcast: https://app.webinar.net/bKQorD7yJqDFor interested individuals u

    3/24/26 4:46:00 PM ET
    $SIDU
    Telecommunications Equipment
    Telecommunications

    $ACRS
    $AEHR
    $AIMD
    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care